Business and Scientific Leadership

MD
Georgetown University School of Medicine

PhD, Physiology
University of Illinois

Allen Mangel, MD, PhD, is a gastroenterologist and Senior Vice President of RTI-HS. Following completion of his medical training, Dr. Mangel did his internship and residency in internal medicine at Duke University Medical Center and then completed his gastroenterology fellowship also at Duke. Following completion of his formal training, he remained on the faculty in the Department of Medicine, Division of Gastroenterology, at Duke for 3 years. Dr. Mangel also has a PhD from the University of Illinois, where his research focused on control of electrical and mechanical activity in gastrointestinal smooth muscle.

After Dr. Mangel left Duke, he joined the gastroenterology clinical research department at Glaxo Wellcome, where he conducted numerous clinical trials and directed product development teams. After departing Glaxo Wellcome, he became Vice-President of Research and Development at Salix Pharmaceuticals. Dr. Mangel has led or participated in numerous FDA interactions, Advisory Committee Presentations, label negotiations, and NDA submissions, and he has over 80 publications.

PhD, Organic Chemistry
Massachusetts Institute of Technology, Cambridge, MA

BS, Organic Chemistry
University of Delaware, Newark, DE

Lawrence Bell, PhD, is the Vice President of Business Affairs for RTI-HS. He has extensive management and hands-on experience consulting for and within the pharmaceutical industry to develop people, processes, and systems related to outcomes research, drug development, and health policy. At RTI-HS he has guided a number of business and technical functions, including Business Development, Office of Quality Assurance, Health Outcomes Strategy, and Health Economics. In addition, he has been extensively involved in the pre-IND (nonclinical) development of two novel chemical entities. He has broad experience with development strategy, including bench and scale-up chemistry, drug and dosage formulation and stability, and clinical trials.

For more than 25 years, he served as a management team member for various divisions and departments of a major pharmaceutical company, establishing and shaping the direction of a number of groups, including Project Planning (tasks and their dependencies, timelines, and costs/budgets to submit INDs and NDAs), Health Economics, Health Policy Research, Clinical Data Processing and Management, and Quality Assurance.

He has published in journals, including PharmacoEconomics, Journal of Medicinal Chemistry, International Journal of Technology Assessment in Health Care, Pharmacotherapy, Epilepsia, Journal of the American Chemical Society, and Journal of Organic Chemistry. Additionally, Dr. Bell was coauthor, coordinator, and editor for Chapter 3, “Estimating Drug Development Costs,” in the report “The Economics of TB Drug Development,” available at http://66.216.124.114/7_1_1GenericNewsArticles.asp?itemId=286

_Report.pdf.

PhD, Economics
MHA, Health Administration
MA, Physiology/Pharmacology
Duke University

Josephine Mauskopf, PhD, MHA, is Vice President of Health Economics at RTI-HS. She has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmacoeconomic research programs for drugs for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, bipolar disease, breast cancer, and HIV infection. She has estimated the cost-effectiveness of antiretroviral drugs, as well as drugs for treating herpes zoster, epilepsy, neonatal respiratory distress syndrome, digoxin toxicity, community acquired pneumonia, intra-abdominal infections, and primary pulmonary hypertension. Dr. Mauskopf also has estimated the impact of an antidepressant on work and social disability. Additionally, she has managed projects to develop or culturally adapt psychometrically valid quality of life measures for migraine, genital herpes, and epilepsy. Dr.Mauskopf has developed Markov models of disease progression for lung cancer and HIV infection and has developed a simulation model of time spent in the operating and recovery rooms.

Dr. Mauskopf was previously Vice President at MEDTAP International, Department Head of Economics Research at Burroughs Wellcome Co., and Director of Pharmacoeconomics Research for Anti-Virals and Anti-Infectives at Glaxo Wellcome Inc. Dr. Mauskopf is Editor-in-Chief of the journal Value in Health. She served for 4 years as a reviewer on the Health Care Technology and Decision Sciences Study Section at the Agency for Healthcare Research and Quality. She has presented her research at numerous national and international symposia. She has also published extensively in journals, including the Journal of the American Medical Association, Journal of Pediatrics, PharmacoEconomics, Medical Care, American Journal of Public Health, Health Services Research, and the American Journal of Cardiology.

JD
University of North Carolina, Chapel Hill, NC

BA, Political Science
Heidelberg College, Tiffin, OH

Dave Obringer, JD, is a member of RTI-HS’s Business Management Team (BMT). The BMT formulates strategic and business plans for the group and oversees implementation of those decisions. He also directs the contracting group supporting RTI-HS and leads review and implementation of strategic alliances and acquisitions. In these roles, he has led or overseen resolution of numerous contract issues in collaboration and/or negotiation with clients and third-party vendors, led or participated in the development and implementation of contracting and procurement processes, and served key roles in the opening of two new RTI-HS offices, one in the United States and one in Spain. He has also served key roles in due diligence activities in two acquisitions in which RTI-HS acquired other entities to expand its service offerings, one in the United States. and one in Canada.

Prior to joining the RTI-HS BMT, Mr. Obringer served as the lead transactional attorney and counsel for three of the four research divisions at RTI (RTI-HS, Social & Statistical Sciences, Science & Engineering), which comprised more than 1,700 research staff and generated more than $330 million in revenue from federal and commercial research and development contracts in fiscal year 2005. In that role, he provided advice and counsel on corporate-wide legal and regulatory matters, including commercial transactions; contract law; federal procurement laws and regulations (FAR, DFAR); identification and protection of intellectual property; publication rights, including copyright issues, data privacy, and control (HIPAA, Privacy Act); US export regulations (EAR, ITAR, and OFAC); conflict of interest determinations; cost accounting standards; corporate acquisitions (asset purchases); and strategic alliance agreements with associated implementing agreements. Mr. Obringer reviewed and approved all contractual and legal documents for the research business units, including nondisclosure agreements, teaming agreements, research contracts, consultant agreements, data use agreements, leases, facility use agreements, source code and intellectual property license agreements, and a variety of other service and consulting agreements. He has provided counsel to RTI’s administrative units, including the risk management, regulatory affairs, property control, human resources, facilities, and purchasing departments, and has consulted with and managed outside counsel as needed. Mr. Obringer also developed and presented training to contract and research staff on topics such as federal procurement, commercial contract law, and conflicts of interest. He managed a large legal/administrative team, including attorneys, contract professionals, and support staff, and served on the corporate steering committee overseeing the procurement and implementation of corporate-wide strategic financial systems.

PhD, Biochemistry
Aberdeen University, Aberdeen, Scotland

DMS, Management
Napier University, Edinburgh, Scotland

PMP, Project Management
PMI (Project Management Institute)

Derek Ross, PhD, is Vice President of Operations at RTI-HS and responsible for Project and Proposal Operations and Editorial Services. He has extensive international experience at a senior level in the pharmaceutical industry leading technical scientific management, project management, and process improvement organizations. Previously, Dr. Ross was Vice President Worldwide Project Planning, Strategy, and Business Re-Design at Glaxo Wellcome, and Vice President Information Technology Portfolio and Project Management at GlaxoSmithKline. He has also founded his own management consulting business, which focuses on building high-performance organizations with emphasis on business strategy and the management of major organizational change.

BA, Accounting
North Carolina State University, Raleigh, NC

Biotechology for Business Executive Education Course
Duke University, Durham, NC

CPA (Certified Public Accountant)

Chris Simmons, CPA, is Vice President of Finance at RTI-HS. Mr. Simmons has spent 20years in financial and operational roles, with particular focus on early stage, rapidly growing technology and biotech businesses. Mr. Simmons began his career at KPMG Peat Marwick and moved to other public accounting firms whose focus was more on early stage businesses. During his 7 years in public accounting, he gained significant experience with building business plans and forecasts for start-ups. Mr. Simmons then moved into corporate finance as controller for Mitsubishi Semiconductor America, Inc., a semiconductor manufacturer. Upon leaving Mitsubishi, Mr. Simmons served 4 years as corporate controller and then vice president of finance for a start-up biotech company, Cogent Neuroscience, Inc. Just prior to joining RTI-HS, Mr Simmons consulted for several other early stage biotech and high-tech businesses as leader of finance

MD
Georgetown University School of Medicine

PhD, Physiology
University of Illinois

Allen Mangel, MD, PhD, is a gastroenterologist and Senior Vice President of RTI-HS. Following completion of his medical training, Dr. Mangel did his internship and residency in internal medicine at Duke University Medical Center and then completed his gastroenterology fellowship also at Duke. Following completion of his formal training, he remained on the faculty in the Department of Medicine, Division of Gastroenterology, at Duke for 3 years. Dr. Mangel also has a PhD from the University of Illinois, where his research focused on control of electrical and mechanical activity in gastrointestinal smooth muscle.

After Dr. Mangel left Duke, he joined the gastroenterology clinical research department at Glaxo Wellcome, where he conducted numerous clinical trials and directed product development teams. After departing Glaxo Wellcome, he became Vice-President of Research and Development at Salix Pharmaceuticals. Dr. Mangel has led or participated in numerous FDA interactions, Advisory Committee Presentations, label negotiations, and NDA submissions, and he has over 80 publications.

PhD, Epidemiology
MPH, Health Policy and Administration
University of North Carolina at Chapel Hill

Elizabeth Andrews, PhD, is the Vice President of Pharmacoepidemiology and Risk Management at RTI-HS. She provides consultation for pharmaceutical companies and the US Food and Drug Administration on therapeutic risk management, and she directs research programs that evaluate drug safety and compliance with prescribing and treatment guidelines. She oversees the conduct of large, prospective patient registries, Web-based surveys, and studies using large prospective databases. Dr. Andrews currently serves as principal investigator on two large risk management programs. Her primary research focus has been on studies of disease natural history, treatment patterns, and drug safety. Her experience has spanned most therapeutic areas, though she has worked extensively in the areas of HIV and sexually transmitted diseases; reproductive health, birth defects, and neonatal health; asthma and COPD; and irritable bowel syndrome. Dr. Andrews is involved in the design of observational research programs within RTI-HS to assure that the methods chosen provide a robust and cost-effective approach to address the study questions and to assure appropriate linkages are forged with academic and governmental partners.

Previously, Dr. Andrews was Vice President, Worldwide Epidemiology, at GlaxoSmithKline and conducted epidemiologic research in a variety of therapeutic areas, including rheumatoid arthritis, genital herpes, HIV, asthma, migraine, and irritable bowel syndrome. She initiated the first pharmaceutical pregnancy registry, the Acyclovir Pregnancy Registry, and multiple registries for other medications. She began her career in the pharmaceutical industry at Burroughs Wellcome in 1982, and subsequently built a strong international epidemiology program at Glaxo Wellcome. Prior to joining Burroughs Wellcome, she managed the Statewide Regionalized Perinatal Care Program and directed the non-Medicaid health care reimbursement programs for the State Health Department of North Carolina.

She is a Fellow and Past President of the International Society for Pharmacoepidemiology, a member of the editorial board of the Journal of Pharmacoepidemiology and Drug Safety, and co-editor of Pharmacovigilance. She is an Adjunct Associate Professor of the University of North Carolina School of Public Health and School of Pharmacy, a senior consultant and investigator with the UNC Center for Education and Research on Therapeutics, and a consultant to the FDA in epidemiology and risk management.

MSc, Operational Research
University of Birmingham, UK

BSc, Mathematics
University of London, UK

Stephen Beard, MSc, is Global Head of Heath Economic and European Operations based in RTI HS’s UK office in Manchester. He has more than 20 years of experience in the application of mathematical modeling, optimization, and decision analysis techniques to business problems gained in academic, government and industrial organizations. He has worked specifically within the health research sector for the past 11 years, having previously held a senior project management and research position within the University of Sheffield, UK, where he headed a team producing rapid review health technology appraisal reports for the National Institute for Clinical Excellence (NICE) in the UK. His work has involved the management of projects using health economics, Markov modeling, and statistical modeling techniques to explore disease progression and the impact of treatment across a range of areas, including colorectal cancer, ovarian cancer, breast cancer, schizophrenia, depression, and infectious diseases. He is a member of the International Society of Pharmacoeconomics Outcomes Research and the Institute for Operations Research and the Management Sciences. He has presented his work at professional conferences and has published in several peer-reviewed journals, including European Journal of Health Economics, British Journal of Cancer, and Pharmacoeconomics.

MBA, Marketing
Indiana University, Indianapolis, IN

MS, Organic Chemistry
Purdue University, Indianapolis, IN

BA, Chemistry and German
Smith College, Northampton, MA

Kati Copley-Merriman, MS, MBA, is Global Head of Regulatory and Health Outcomes Strategy at RTI-HS. Ms. Copley-Merriman has more than 25 years of industry experience, including leadership roles in Global Outcomes Research at Eli Lilly, Parke-Davis, and Pfizer. She has experience in all aspects of Outcomes Research, including clinical trial design with PRO endpoints, economic evaluations, OR strategic plans, and regulatory strategy. In her outcomes research and regulatory role, she leads a team of scientists responsible for developing OR strategic plans for phase 2/3 compounds, developing PRO dossiers for the FDA for Label Claims, and designing clinical trials with OR endpoints. Ms. Copley-Merriman has experience in many therapeutic areas, including oncology, pain and inflammation, dermatology, respiratory, urology, and CNS.

Janice D’Angelo is the Global Head of Pricing and Reimbursement in RTI-HS’s Canadian Office. She is the co-founder of Palmer D’Angelo Consulting Inc. (PDCI), which was acquired by RTI-HS in January 2007. She provides expert advice to clients with respect to the Guidelines and Regulations of the Canadian Patented Medicine Prices Review Board (PMPRB) and coordinates RTI-HS’s pricing and reimbursement research projects. She has over 20 years of regulatory experience with the federal government of Canada. From 1991 to 1996, she was employed by the PMPRB and was responsible for operational policy development, the resolution of non-standard reviews, and a wide range of compliance activities. As Chief of Compliance, she oversaw the application of the Excessive Price Guidelines by the Board’s Compliance Officers. Prior to 1991, Janice D’Angelo conducted economic and statistical analysis for the National Energy Board (NEB) relating to Canada’s oil supply and demand and was responsible for various regulatory activities including the advancement of export application through the NEB’s public hearing process.

PhD, Clinical Psychology
MS, Clinical Psychology
Oklahoma State University, Stillwater, OK

BA, Psychology
Millsaps College, Jackson, MS

Dana Britt DiBenedetti, PhD, Head of Patient-Reported Outcomes at RTI-HS, is a licensed clinical health psychologist with extensive experience in psychosocial assessment of adults and children in numerous therapeutic areas. Her broad clinical and assessment experience includes expertise in psychiatry, women’s health (e.g., menopause, vaginal atrophy, endometriosis), sexual medicine (e.g., erectile dysfunction, female sexual dysfunction, Peyronie’s disease), nicotine dependence, obesity, chronic pain, oncology, and neurology/neuropsychology. Currently, Dr. DiBenedetti specializes in the development of questionnaires designed to measure quality of life, patient satisfaction, and other patient-reported outcomes. As part of the questionnaire-development process, Dr. DiBenedetti has facilitated numerous patient, caregiver, and physician focus groups, and conducted cognitive interviews with a wide variety of patient and professional populations. Dr. DiBenedetti has considerable experience in both academic and pharmaceutical settings with instrument development and validation; coordination of instrument translations; and protocol design, functional status and quality of life assessment, and study implementation in phase 2 through phase 4 clinical studies. Dr. DiBenedetti has authored/coauthored numerous manuscripts and scientific presentations on quality of life, treatment satisfaction, and other outcomes in various patient populations, and served as a reviewer for several journals, including Journal of Consulting and Clinical Psychology, Health Psychology, Annals of Behavioral Medicine, International Journal of Behavioral Medicine, Addictive Behaviors, and Medical Care.

PhD, Industrial Engineering, concentrating in the areas of Operations Research and Management, Dissertation: Determining an Allocation of Trainers and Field Representatives to Training Sites and Start Times
MS, Industrial Engineering concentrating in Operations Research
North Carolina State University, Raleigh, NC

BS, Mathematical Science concentrating in Operations Research
University of North Carolina, Chapel Hill, NC

Stephanie Earnshaw, PhD, is Vice President of US Health Economics at RTI-HS. Dr. Earnshaw applies mathematical modeling, optimization, and decision-analysis techniques to industry-related issues and health care problems. Her areas of specialization include systems optimization and solving resource allocation problems. She has developed innovative mathematical models to determine pricing strategy, budget impact, and cost-effectiveness of new products. Dr. Earnshaw has developed a variety of mathematical models, including Markov models, Monte Carlo simulation models, and other state transition models, to analyze the effect of new medical drugs and devices. She has developed innovative mathematical models to determine allocations of HIV prevention interventions and trainers and field representatives to training sites. To solve these models, she has used various heuristic, linear programming, and integer programming techniques. In addition to her modeling background, Dr. Earnshaw has extensive programming experience. She has programmed cost-effectiveness, budget-impact, and allocation models along with operations research algorithms such as genetic algorithms, simulated annealing algorithms, linear and integer programming algorithms, and network algorithms. She also has led programmers in developing user interfaces for health surveys and for pharmacoeconomic models. More recently, Ms. Earnshaw provided expert guidance on the creation of an economic model predicting AIDS survival by adherence level, which was highlighted in the December 2006 issue of AIDS Alert. Dr. Earnshaw has experience in quality management, machine scheduling, linear and integer programming, network optimization, stochastic modeling, and personnel-assignment models. She is a member of the International Society of Pharmacoeconomics Outcomes Research and the Institute for Operations Research and the Management Sciences. She has presented her work at professional conferences and has published in several peer-reviewed journals, including Annuals of Internal Medicine, Medical Decision Making, Journal of American Society of Nephrology, Stroke, and Pharmacoeconomics.

PhD, Quantitative Psychology
MA, Clinical Psychology
University of North Carolina, Chapel Hill, NC

BS, Mathematics and Psychology
Duke University, Durham, NC

Sheri Fehnel, PhD, is Vice President of Patient-Reported Outcomes in RTI-HS. Since joining the RTI staff in 1988, she has combined the study of clinical psychology and psychometrics with practical research and clinical experience. She specializes in the development and evaluation of questionnaires designed to measure health-related quality of life, functional status, patient satisfaction, resource utilization, and other patient-reported outcomes. This work has involved a wide range of therapeutic areas, including depression, attention-deficit disorder, bipolar disorder, schizophrenia, insomnia, incontinence, irritable bowel syndrome, oncology, cardiovascular disease, women’s health, diabetes, asthma, COPD, sexual dysfunction, obesity, cystic fibrosis, chronic pain, and sexually transmitted diseases such as herpes, HPV, and HIV/AIDS. As part of the questionnaire-development process, Dr. Fehnel has moderated countless focus groups, conducted cognitive interviews with a wide variety of patient and professional populations, and assessed potential sources of measurement error through cognitive forms appraisal. She has also evaluated the psychometric properties of many survey and clinical instruments using techniques such as factor analysis, structural equations modeling, and item response theory.

Dr. Fehnel is a frequent presenter at annual conferences held by organizations such as the International Society for Quality of Life Research (ISOQOL) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), as well as at various Drug Information Association (DIA) symposia. She also has published a number of articles related to questionnaire development and psychometric evaluation in Quality of Life Research, Medical Care, and Pharmacoeconomics.

BSN, Family Nurse Practitioner
Purdue University Calumet, Hammond, IN

Associate of Applied Science
Purdue University North Central, Westville, IN

Lynne Hamm is Senior Director of Clinical and Medical Services at RTI-HS. She has extensive experience in the pharmaceutical industry designing, implementing, and managing Phase II-IV clinical studies. Ms. Hamm has developed specifications for interactive voice response systems (IVRS) to facilitate the electronic capture of subject diary data and has experience using IVRS in large international studies. Ms. Hamm has been involved with multiple clinical studies in the United States, Canada, Mexico, and Europe. She has experience with national call centers and script development to assist in subject referral to study sites in response to nationwide study recruitment advertising. While working in the pharmaceutical industry, Ms. Hamm has been involved in protocol design, study report writing, preparations for FDA Advisory Committees, and NDA submissions.

PhD, Economics
Dissertation: An Analysis of Nesting Structure in the Multinomial Logit Model
MA, Economics
University of Delaware, Newark, DE

Bachelor of Business Administration (summa cum laude)
Temple University, Philadelphia, PA

Brett Hauber, PhD, is Senior Economist and Head of Health Preference Assessment at RTI-HS. He has more than 10 years of academic, research, and government experience in health and environmental economics. His primary area of specialization is discrete choice analysis of revealed- and stated-preference data. He also has extensive experience in conducting benefit-risk analysis of patients and other health care decision makers and in estimating health-state utilities. His most recent applied work has included discrete-choice experiments of patient and physician benefit-risk preferences for treatments for Alzheimer’s disease, HIV, vasomotor symptoms, Crohn’s disease, and irritable bowel syndrome. He has also studied the theoretical and empirical relationships among various health utility measures. Dr. Hauber regularly teaches courses on conjoint analysis and health-state utility estimation. Dr. Hauber’s research has been published in Value in Health, Pharmacoeconomics, Quality of Life Research, Journal of Women’s Health, Medical Care, Clinical Therapeutics, ISPOR Connections, The Patient, Land Economics, and the Journal of the American Agricultural Association.

PhD, Epidemiology
University of Pittsburgh, Pittsburgh, PA

MSc, Statistics
Queen’s University, Kingston, Ontario, Canada

BSc (Hon.), Psychology
Lakehead University, Thunder Bay, Ontario, Canada

William D. Irish, PhD, is Vice President of Biometrics with more than 20 years of experience in managing statistical and programming staff in health research. He brings to RTI-HS knowledge and expertise in planning, studying, and reporting on health-outcomes research, and multisite epidemiologic and large database studies. Dr. Irish has extensive experience in the application of statistical analyses to pharmaceutical development projects. He has played a key role in clinical development, clinical trial protocol design and analysis, statistical analysis plans, randomization and blinding procedures, sample size estimation, and data management (data validation and quality assurance).

In the pharmaceutical industry, he has been a leader in the phase 2/3 development of successful drugs and devices and has been responsible for all statistical aspects of submission, including interaction with regulatory agencies. He has collaborated with clinical investigators internationally in study design and analysis, implemented large-scale database validation efforts, and directed analysis/programming teams. Dr. Irish’s major research interests include statistical modeling and prediction, large database analyses, survival analysis techniques, competing risk analysis, and clinical trials methodology. Dr. Irish holds faculty positions, lectures regularly, and keeps current in various statistical associations and committees. He is an accomplished epidemiologist/biostatistician who has published extensively on transplantation and immunologic issues. He is currently Chair of a DSMB for a new class of drug for prevention of delayed graft function in kidney transplant patients. He has written abstracts, reviews, and articles for journals such as Transplantation, Journal of American Society of Nephrology, Annals of Surgery, Annals of Internal Medicine, and Liver Transplantation and Surgery. He is a member of several professional organizations, including the American Society of Transplantation, Drug Information Association, and the American Statistical Association. He is a member of the Clinical Research Committee for the American Society of Transplantation, which develops the endpoints for transplant-related clinical trials.

PhD, Economics
MA, Economics
State University of New York, Stony Brook, NY

BA, Economics
Occidental College, Los Angeles, CA

F. Reed Johnson, PhD, has more than 35 years of academic and research experience in health and environmental economics. He has served on the faculty of several universities in the United States, Canada, and Sweden. As a staff member in the US Environmental Protection Agency’s environmental economics research program during the 1980s, Dr. Johnson helped pioneer development of basic nonmarket valuation techniques. These techniques are now widely used for cost-benefit analysis in health and environmental economics. He has designed and analyzed numerous surveys for measuring willingness to pay for health-risk reduction and improved environmental quality. He also has developed and researched various value elicitation methods, including direct questions, discrete choice, graded pairs, and other approaches. Dr. Johnson has extensive experience in using advanced statistical techniques to analyze censored, truncated, and discrete survey data.

Dr. Johnson has more than 80 publications in books and peer-reviewed journals. His research has been published in various clinical journals, Review of Economics and Statistics, Journal of Health Economics, Medical Decision Making, Health Economics, Value in Health, Journal of Environmental Economics and Management, Journal of Policy Analysis and Management, Land Economics, and other journals. He has coauthored a recent book on various techniques for using existing environmental and health value estimates for policy analysis. His current research involves estimating general time equivalences among health states and patients’ willingness to accept side-effect risks in return for therapeutic benefits.

PhD, Economics
MHA, Health Administration
MA, Physiology/Pharmacology
Duke University

Josephine Mauskopf, PhD, MHA, is Vice President of Health Economics at RTI-HS. She has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmacoeconomic research programs for drugs for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, bipolar disease, breast cancer, and HIV infection. She has estimated the cost-effectiveness of antiretroviral drugs, as well as drugs for treating herpes zoster, epilepsy, neonatal respiratory distress syndrome, digoxin toxicity, community acquired pneumonia, intra-abdominal infections, and primary pulmonary hypertension. Dr. Mauskopf also has estimated the impact of an antidepressant on work and social disability. Additionally, she has managed projects to develop or culturally adapt psychometrically valid quality of life measures for migraine, genital herpes, and epilepsy. Dr.Mauskopf has developed Markov models of disease progression for lung cancer and HIV infection and has developed a simulation model of time spent in the operating and recovery rooms.

Dr. Mauskopf was previously Vice President at MEDTAP International, Department Head of Economics Research at Burroughs Wellcome Co., and Director of Pharmacoeconomics Research for Anti-Virals and Anti-Infectives at Glaxo Wellcome Inc. Dr. Mauskopf is Editor-in-Chief of the journal Value in Health. She served for 4 years as a reviewer on the Health Care Technology and Decision Sciences Study Section at the Agency for Healthcare Research and Quality. She has presented her research at numerous national and international symposia. She has also published extensively in journals, including the Journal of the American Medical Association, Journal of Pediatrics, PharmacoEconomics, Medical Care, American Journal of Public Health, Health Services Research, and the American Journal of Cardiology.

PhD, Quantitative Psychology
MA, Quantitative Psychology
University of North Carolina, Chapel Hill, NC

BS, Statistics, Mathematics Education (graduated Summa Cum Laude)
North Carolina State University, Raleigh, NC

Lori McLeod, PhD, is Head of Psychometrics at RTI-HS. Dr.McLeod is a trained psychometrician with over 10 years of experience in instrument development and validation, as well as experience conducting systematic assessments of clinical and economic literature and developing appropriate health outcome strategies. In her Psychometrics role, she has conducted many psychometric evaluations of both paper-and-pencil and computer-administered instruments. These investigations have included the assessment of scale reliability, validity, responsiveness, and work to define minimal important differences. Dr.McLeod has published numerous related manuscripts in Applied Psychological Measurement, Pharmacoeconomics, Journal of Educational Measurement, and Psychometrika. She has experience in a wide variety of therapeutic areas, including chronic pain, dermatology, oncology, psychiatry, respiratory, sleep disorders, urology, and sexual dysfunction.

Graduate coursework (24 hours), Master of Health Sciences
Duke University School of Medicine, Durham, NC

BA, Economics
University of North Carolina, Charlotte, NC

Deirdre Mladsi has nearly 20 years of experience conducting health economics and outcomes research, including 5 years in the Global Health Outcomes group of a leading research-based pharmaceutical company. As a consultant, Ms. Mladsi, one of the founding senior members of RTI HS, has served as a Director of Health Economics and the Global Head of Health Outcomes Strategy, before organizing RTI-HS’s pricing and reimbursement service offering. As a Head of Pricing and Reimbursement, Ms. Mladsi works with local pricing and reimbursement experts in markets around the world, conducts payer research, maps the global competitive landscape for new products, and tracks market developments. These activities culminate in the development of global strategies to maximize product value. Ms.Mladsi also serves as an internal RTI-HS resource, bringing a market-oriented perspective to health economics and outcomes research projects, ensuring that they are conducted with an appreciation of the Value Messages that will result. She provides senior expertise to a team of health outcomes scientists and medical writers that specializes in designing and communicating the results of value-driven research. The team does this by developing and testing Value Messages, designing value-driven research strategies and plans, creating Value Dossiers, and preparing pricing and reimbursement dossiers for major markets. In addition to pricing and reimbursement issues, her interest is in bringing together scientists and marketing professionals to ensure that clear, concise, and relevant information is placed in the hands of marketplace decision makers, facilitating patient access to valuable new pharmaceutical products.

Her training is in economics and applied biostatistics, with an emphasis on clinical research. Although she has worked in all primary therapeutic areas, for several years her primary focus was oncology. She has published (also under the name Neighbors) in the Journal of Clinical Oncology, Journal of Pain and Symptom Management, Journal of Health Economics, Pharmacoeconomics, and Current Medical Research and Opinion, and has presented at numerous professional conferences. She has served as an adjunct faculty of Campbell University, responsible for their Health Economics course, offered as part of their Master’s in Clinical Research program.

Neil Palmer is Vice President of Pricing and Reimbursement at RTI-HS. Formerly Principal Consultant of Palmer D’Angelo Consulting Inc., Canada’s leading pricing and reimbursement consultancy, Mr. Palmer is responsible for leading RTI-HS’s pricing, reimbursement, and policy research assignments. Mr. Palmer worked with the Canadian Patented Medicine Prices Review Board, where his responsibilities included policy development, overseeing the price review of patented medicines, and conducting economic research. Prior to this, he worked with the Health Division of Statistics Canada, where he was responsible for economic and statistical analysis of health care costs and utilization. After completing his studies at the University of Western Ontario, Mr. Palmer began his career in Montreal with the research group of the Kellogg Centre for Advanced Studies in Primary Care. He has written extensively on pharmaceutical pricing and reimbursement issues and is a frequent speaker at pharmaceutical conferences in North America and Europe.

MD, PhD
Universitat de Barcelona, Barcelona, Spain

MPH, Postdoctoral Fellowship
Johns Hopkins University, Baltimore, MD, USA

Susana Perez-Gutthann, MD, MPH, PhD, FISPE, FRCP, is Vice President and Global Head of Epidemiology at RTI-HS. Dr. Perez-Gutthann holds medical and doctoral degrees from the University of Barcelona, and a Master of Public Health with a concentration in epidemiology from Johns Hopkins University. Her prior positions include global and European head of epidemiology at Pfizer, Pharmacia, Novartis, and Ciba-Geigy, and a postdoctoral fellow in the Division of Clinical Epidemiology at Johns Hopkins. Dr.Perez-Gutthann has 18 years of experience in research-driven multinational pharmaceutical companies, developing and leading teams of epidemiologists and driving strategy and research programs for safety, pharmacovigilance, risk management, development, and regulatory activities applying public health and epidemiological methods.

Dr. Perez-Gutthann is an active leader and past president of the International Society of Pharmacoepidemiology (ISPE). She is a Fellow of ISPE and of the Royal College of Physicians, Edinburgh. She is invited to speak and chair conferences and symposia, which have included DIA, TOPRA, Australian National Prescribing Service Symposium, Asian Pacific Regulatory Safety Sciences Meeting, International Conference of Pharmacoepidemiology & Risk Management, and World Congress of Pharmacology and Clinical Therapeutics. Dr. Perez-Gutthann’s roles as an advisor and in international working groups have included WHO TRD Product Development and Evaluation, International Scientific Advisory Board to MHRA General Practice Research Database, Avon Longitudinal Study of Parents and Children (ALSPAC) Drug Safety Advisory Committee, ISPE Working Groups on Risk Management Guidances (FDA, EMEA), Good Pharmacoepidemiology Practice, and confidentiality of patient databases in Europe; working groups on gastrointestinal complications associated with NSAIDs, IMBRF on drug-induced disease, and HRT and breast cancer risk. Currently Dr. Perez-Gutthann serves as member and chair of several study advisory boards.

DrPH
MPH
Harvard School of Public Health, Boston, MA

DMD
Harvard School of Dental Medicine, Boston, MA

AB
Colgate University, Hamilton, NY

Kenneth J. Rothman, DrPH, is a Distinguished Fellow and Vice President for Epidemiology Research at RTI-HS. He is also Professor of Epidemiology and Medicine at Boston University. His main career interest has been the development and teaching of the concepts and methods of epidemiologic research. He has authored or coauthored more than 250scholarly publications, most of which are original epidemiologic research studies. His research has spanned a wide range of health problems, including cancer, cardiovascular disease, neurologic disease, birth defects, injuries, environmental exposures, and adverse effects of pharmaceutical agents. In addition to publishing original research, he has devoted time to several other efforts related to the conduct of research. He has written extensively on ethical issues relating to the conduct of science. He regularly teaches intensive courses on epidemiologic research principles in the US and abroad. He has also dedicated a large proportion of his professional effort to editorial activities and publishing. He was the founding editor of the journal Epidemiology, and has served as Assistant Editor of the American Journal of Public Health, Editor of the American Journal of Epidemiology, a member of the Editorial Board of the New England Journal of Medicine and the International Advisory Board of the Lancet. He is a Past President of the Society for Epidemiologic Research, an Honorary Fellow of the American College of Epidemiology, Fellow and member of the Board of Directors and Fellow of the International Society for Pharmacoepidemiology. He has written two widely read epidemiologic textbooks: Modern Epidemiology, first published in 1986 by Little, Brown and Co., which is a comprehensive advanced text of epidemiologic methods, and Epidemiology: An Introduction, published in 2002 by Oxford University Press.

PhD, Anatomy and Embryology
University of London, London, UK

MD
Harvard Medical School/Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA

MBA
University of North Carolina, Chapel Hill, NC

AB, Chemistry and Physics
Harvard College, Cambridge, MA

Brad Walters, MD, PhD, MBA, is a Senior Director of Clinical and Medical Services at RTI-HS and Chief Medical Officer of RTI International. After completing his PhD at University College London and his MD at Harvard Medical School, Dr.Walters did a surgical internship at Johns Hopkins Hospital and a neurological surgery residency at the Massachusetts General Hospital. He then joined the faculty of the University of North Carolina (UNC) at Chapel Hill School of Medicine, where he established the radiosurgery program (with colleagues from radiation oncology) and epilepsy surgery program (with colleagues from neurology). His basic research focused on central nervous system trauma.

While at UNC, Dr. Walters enrolled in the Kenan-Flagler Business School, and after completion of his MBA joined Academy Funds, a pre-seed and seed stage venture capital firm specializing in the commercialization (via spin-outs) of intellectual property based on university research. As Principal and then Partner, he served on the Boards of Directors of Kucera Pharmaceutical Company, ParinGenix, and Curry Pharmaceuticals. While at Academy, Dr. Walters was appointed a member of the Building Entrepreneurial Companies Work Group of the North Carolina Biotechnology Center Strategic Plan, and also to the Governor’s Task Force on Nanotechnology and North Carolina’s Economy. From 1999 through 2006, he served as a member of the Board of Directors of NCHICA.

For the 2 years prior to joining RTI-HS, Dr. Walters was an independent life sciences consultant. Most recently he focused on phase 1 and phase 2 projects, where he performed clinical trial design, data analysis, data interpretation, and medical writing. He has been involved with regulatory submissions to the FDA and European Competent Authorities for clinical trials running in the United States, Belgium, Germany, Switzerland, and Canada. He continues to serve on the Science Advisory Board of UNC-Greensboro, and the Committee for the Protection of the Rights of Human Subjects at UNC-Chapel Hill.

MBA, Business Administration
University of North Carolina, Chapel Hill, NC

BSc, Bachelor of Science
University of British Columbia, Vancouver, BC

BA, Business Administration
Fresno Pacific College, Fresno, CA

Graham Dyck, MBA, is a creative manager with 16 years of experience in product management, business development, marketing, and domestic and international sales. He is skilled in team facilitation with strengths in communication. He is an innovative, bottom line–oriented manager with excellent strategic marketing and financial analysis skills and strong interpersonal skills. Mr. Dyck’s experience includes business plan development, profit and loss management, strategic market analysis, forecasting and budgeting, marketing communications, business to business sales, negotiating licensing agreements, and product launch planning.

BSc, Nutrition and Dietetics
University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Elizabeth Resch is a Manager of Business Development at RTI-HS and has an emphasis on business development initiatives for the pricing and reimbursement group. She is also responsible for managing the group’s Canadian market access publications, including the “Canadian Drug Benefit Plans Reference Guide.” She studied at McGill University and received a Bachelor of Science from the University of Saskatchewan with a major in Nutrition and Dietetics. Ms. Resch has worked in the pharmaceutical industry, clinical research, and the public and private health care sectors.

PhD, Anatomy and Embryology
University of London, London, UK

MD
Harvard Medical School/Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA

MBA
University of North Carolina, Chapel Hill, NC

AB, Chemistry and Physics
Harvard College, Cambridge, MA

Brad Walters, MD, PhD, MBA, is a Senior Director of Clinical and Medical Services at RTI-HS and Chief Medical Officer of RTI International. After completing his PhD at University College London and his MD at Harvard Medical School, Dr.Walters did a surgical internship at Johns Hopkins Hospital and a neurological surgery residency at the Massachusetts General Hospital. He then joined the faculty of the University of North Carolina (UNC) at Chapel Hill School of Medicine, where he established the radiosurgery program (with colleagues from radiation oncology) and epilepsy surgery program (with colleagues from neurology). His basic research focused on central nervous system trauma.

While at UNC, Dr. Walters enrolled in the Kenan-Flagler Business School, and after completion of his MBA joined Academy Funds, a pre-seed and seed stage venture capital firm specializing in the commercialization (via spin-outs) of intellectual property based on university research. As Principal and then Partner, he served on the Boards of Directors of Kucera Pharmaceutical Company, ParinGenix, and Curry Pharmaceuticals. While at Academy, Dr. Walters was appointed a member of the Building Entrepreneurial Companies Work Group of the North Carolina Biotechnology Center Strategic Plan, and also to the Governor’s Task Force on Nanotechnology and North Carolina’s Economy. From 1999 through 2006, he served as a member of the Board of Directors of NCHICA.

For the 2 years prior to joining RTI-HS, Dr. Walters was an independent life sciences consultant. Most recently he focused on phase 1 and phase 2 projects, where he performed clinical trial design, data analysis, data interpretation, and medical writing. He has been involved with regulatory submissions to the FDA and European Competent Authorities for clinical trials running in the United States, Belgium, Germany, Switzerland, and Canada. He continues to serve on the Science Advisory Board of UNC-Greensboro, and the Committee for the Protection of the Rights of Human Subjects at UNC-Chapel Hill.

BS, Pharmacy
Albany College of Pharmacy, Albany, NY

Peter Wirth, RPH, Senior Director of Business Development at RTI-HS, provides support of the business development activities for the entire portfolio of RTI-HS services. He applies various skills based on his 20 years of pharmaceutical industry experience. He has a wide range of experience in customer relationships, people management, sales, medical and drug information, marketing support, clinical trials, and product safety. He is involved in developing strategic alliances that support the needs and goals of RTI-HS’s clients.

Mr. Wirth is a pharmacist who began his career in 1988 working with GSK as a pharmaceutical representative in Monterey, CA. In 1992 he relocated to North Carolina and joined Ask the Pharmacist, a nationally known leader in the provision of medical and drug information services. He served as the VP of Sales and Client Operations and became responsible for operations, training, QA, HR, IT, and sales and marketing. During this time, Mr. Wirth was involved in the launch of more than 35 products, as well as several drug recall/withdrawal projects. In 1999, PPD acquired Ask the Pharmacist and Mr. Wirth was appointed as Senior Business Development Executive for PPD Market Development. He focused on selling their late-phase suite of services, which included product safety, medical writing, marketing-support programs, patient registries, postmarket studies (phase 3b/4), and medical and drug information. He also sold their risk management, health outcomes, and Rx-to-OTC switch studies. In 2004, Mr. Wirth joined Ninaza, Inc. as Director of Business Development and marketed their electronic data collection (EDC) services.

PhD, Economics
MHA, Health Administration
MA, Physiology/Pharmacology
Duke University

Josephine Mauskopf, PhD, MHA, is Vice President of Health Economics at RTI-HS. She has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmacoeconomic research programs for drugs for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, bipolar disease, breast cancer, and HIV infection. She has estimated the cost-effectiveness of antiretroviral drugs, as well as drugs for treating herpes zoster, epilepsy, neonatal respiratory distress syndrome, digoxin toxicity, community acquired pneumonia, intra-abdominal infections, and primary pulmonary hypertension. Dr. Mauskopf also has estimated the impact of an antidepressant on work and social disability. Additionally, she has managed projects to develop or culturally adapt psychometrically valid quality of life measures for migraine, genital herpes, and epilepsy. Dr.Mauskopf has developed Markov models of disease progression for lung cancer and HIV infection and has developed a simulation model of time spent in the operating and recovery rooms.

Dr. Mauskopf was previously Vice President at MEDTAP International, Department Head of Economics Research at Burroughs Wellcome Co., and Director of Pharmacoeconomics Research for Anti-Virals and Anti-Infectives at Glaxo Wellcome Inc. Dr. Mauskopf is Editor-in-Chief of the journal Value in Health. She served for 4 years as a reviewer on the Health Care Technology and Decision Sciences Study Section at the Agency for Healthcare Research and Quality. She has presented her research at numerous national and international symposia. She has also published extensively in journals, including the Journal of the American Medical Association, Journal of Pediatrics, PharmacoEconomics, Medical Care, American Journal of Public Health, Health Services Research, and the American Journal of Cardiology.

MSc, Operational Research
University of Birmingham, UK

BSc, Mathematics
University of London, UK

Stephen Beard, MSc, is Global Head of Heath Economic and European Operations based in RTI HS’s UK office in Manchester. He has more than 20 years of experience in the application of mathematical modeling, optimization, and decision analysis techniques to business problems gained in academic, government and industrial organizations. He has worked specifically within the health research sector for the past 11 years, having previously held a senior project management and research position within the University of Sheffield, UK, where he headed a team producing rapid review health technology appraisal reports for the National Institute for Clinical Excellence (NICE) in the UK. His work has involved the management of projects using health economics, Markov modeling, and statistical modeling techniques to explore disease progression and the impact of treatment across a range of areas, including colorectal cancer, ovarian cancer, breast cancer, schizophrenia, depression, and infectious diseases. He is a member of the International Society of Pharmacoeconomics Outcomes Research and the Institute for Operations Research and the Management Sciences. He has presented his work at professional conferences and has published in several peer-reviewed journals, including European Journal of Health Economics, British Journal of Cancer, and Pharmacoeconomics.

PhD, Industrial Engineering, concentrating in the areas of Operations Research and Management, Dissertation: Determining an Allocation of Trainers and Field Representatives to Training Sites and Start Times
MS, Industrial Engineering concentrating in Operations Research
North Carolina State University, Raleigh, NC

BS, Mathematical Science concentrating in Operations Research
University of North Carolina, Chapel Hill, NC

Stephanie Earnshaw, PhD, is Vice President of US Health Economics at RTI-HS. Dr. Earnshaw applies mathematical modeling, optimization, and decision-analysis techniques to industry-related issues and health care problems. Her areas of specialization include systems optimization and solving resource allocation problems. She has developed innovative mathematical models to determine pricing strategy, budget impact, and cost-effectiveness of new products. Dr. Earnshaw has developed a variety of mathematical models, including Markov models, Monte Carlo simulation models, and other state transition models, to analyze the effect of new medical drugs and devices. She has developed innovative mathematical models to determine allocations of HIV prevention interventions and trainers and field representatives to training sites. To solve these models, she has used various heuristic, linear programming, and integer programming techniques. In addition to her modeling background, Dr. Earnshaw has extensive programming experience. She has programmed cost-effectiveness, budget-impact, and allocation models along with operations research algorithms such as genetic algorithms, simulated annealing algorithms, linear and integer programming algorithms, and network algorithms. She also has led programmers in developing user interfaces for health surveys and for pharmacoeconomic models. More recently, Ms. Earnshaw provided expert guidance on the creation of an economic model predicting AIDS survival by adherence level, which was highlighted in the December 2006 issue of AIDS Alert. Dr. Earnshaw has experience in quality management, machine scheduling, linear and integer programming, network optimization, stochastic modeling, and personnel-assignment models. She is a member of the International Society of Pharmacoeconomics Outcomes Research and the Institute for Operations Research and the Management Sciences. She has presented her work at professional conferences and has published in several peer-reviewed journals, including Annuals of Internal Medicine, Medical Decision Making, Journal of American Society of Nephrology, Stroke, and Pharmacoeconomics.

PhD, Economics
MA, Economics
University of Virginia, Charlottesville, VA

BA, Business and Commerce
Keio University, Tokyo, Japan

Naoko Akashi-Ronquest, PhD, is an Associate Director of Health Economics at RTI-HS. Prior to joining RTI-HS, Dr.Akashi-Ronquest taught microeconomic theory, econometrics, and applied econometrics in SAS at California State University, Fullerton. She has conducted numerous empirical health economics studies, including her doctoral thesis on the effects of managed care organizations’ restrictions on patients’ well-being.

MA, Applied Economics
University of North Carolina, Greensboro, NC

MA, Economics
PGDFT, Post Graduate Diploma in Foreign Trade
BA, Economics
University of Pune, Pune, India

Bela Bapat, MA, is a research health economist at RTI-HS. Prior to joining RTI-HS, Ms.Bapat worked in the field of health services and health economic research in RTI’s Public Health Economics Program. She has extensive experience in database analysis, specifically retrospective health care claims database analysis, state cancer registry data analysis, and cross-sectional and longitudinal survey analyses. Ms. Bapat has conducted research to estimate the prevalence and economic burden of contrast-induced nephropathy and chronic kidney disease. She has also worked on several high-profile cost-effectiveness evaluations for the Centers for Disease Control and Prevention (CDC) such as evaluation of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) and Colorectal Cancer Screening Demonstration Project (CRCSDP). She also has extensive knowledge and experience in data collection methodologies, including development of data collection tools, chart abstraction, and surveys. Ms. Bapat has conducted research to estimate the prevalence and economic burden of various medical conditions, including meningococcal disease, abdominal adhesiolysis, Dupuytren’s contracture, adhesive capsulitis, Peyronie's disease, chronic hepatitis C, colorectal cancer, breast cancer, cervical cancer, oral cancer, chronic kidney disease, and contrast-induced nephropathy.

Ms. Bapat has coauthored research published in the Journal of Medical Economics, Cancer, Preventing Chronic Disease, and Bulletin of the World Health Organization. Her research has also been accepted for presentation at numerous professional conferences and workshops, including the North American Congress of the International Society for Pharmacoeconomics and Outcomes Research, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 9th Annual European Congress, Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, the CDC’s Cancer Conference and the Academy of Health’s annual meetings.

Currently undertaking PhD in evaluation of ePAQ: an online assessment tool for women’s health

MSc, Health Economics and Management
Sheffield University, Sheffield, United Kingdom

BSc, Physiotherapy
Coventry University, Coventry, United Kingdom

Victoria Brennan, MSc, is a Health Economics Researcher at RTI-HS. Ms. Brennan has a broad spectrum of experience in both the clinical and academic settings. Clinically, she has 8years of experience working as a physiotherapist specializing in elderly care, and also worked as a Senior Lecturer in physiotherapy at Sheffield Hallam University.

She undertook an MSc in Health Economics and Management and is currently undertaking a PhD at Sheffield University in Health Economics. She has also worked with The University of Sheffield and UK Department of Health on the evaluation of modernization programs for elderly care in the NHS. Her work has been presented at the European Respiratory Society’s annual meeting and at the ISPOR 13th Annual International Meeting in Toronto in 2008. In addition to this, Ms Brennan has traveled to Mbarara Hospital in Uganda to work as a voluntary physiotherapist and lecturer.

Since working at RTI-HS, MS. Brennan has undertaken targeted literature reviews and systematic reviews of economic evaluations; supported the writing, development, and presentation of manuscripts and posters for publication; and contributed to the development of cost-effectiveness, cost-utility, and budget-impact models in Microsoft Excel, as well as project managing cost-effectiveness studies. Therapeutic areas include rheumatoid arthritis, breast cancer, NSCLC, and VTE.

PhD, Operations Research
MSc, Operations Research
University of North Carolina, Chapel Hill, NC

BS, Mathematics
Harvey Mudd College, Claremont, CA

Anita Brogan, PhD, is a Senior Director of Health Economics at RTI-HS. Dr. Brogan uses analytical techniques to assess and present the clinical and economic value of emerging pharmaceutical and biotechnology products. She has developed cost-effectiveness, budget-impact, and population models; cost-consequence analyses; and product value dossiers. She has experience with all types of modeling procedures, including Markov and other stochastic models, simulation, regression, linear and nonlinear programming, and various types of sensitivity analysis. Dr. Brogan has extensive experience with programming models, user-friendly interfaces, and other software applications using the Visual Basic for Applications language in Excel. She is proficient with various other programming languages and mathematical and statistical software packages. Dr. Brogan has developed models and analyses in the areas of HIV, influenza, diabetic nephropathy, colorectal cancer, breast cancer, non-Hodgkin’s lymphoma, osteoporosis, chronic pain, age-related macular degeneration, schizophrenia, bipolar disorder, epilepsy, bone healing, hospital-acquired infection, financial portfolio optimization, and vehicle routing. Her research has been presented at various professional conferences and published in the European Journal of Operational Research, IIE Transactions, and the Journal of Parenteral and Enteral Nutrition.

PhD, Pharmacy Practice and Administration, in progress
The Ohio State University, Columbus, OH

Completed all PhD coursework in Health Policy and Administration
University of North Carolina, Chapel Hill, NC

MS, Economics
BS, Economics
BS, Biology
Florida State University, Tallahassee, FL

Sean Candrilli, MS, is a Senior Director in Health Economics at RTI-HS. During his tenure at RTI-HS, he has worked extensively in the area of data management and analyses of clinical trial and commercially available and public use databases. His academic experience is heavily grounded in applied economics and econometrics, particularly as related to public health topics, and he has extensive experience in all aspects of retrospective health care claims database analyses, cross-sectional and longitudinal survey analyses, econometric modeling, and data management using a variety of statistical packages, including SAS and Stata. Mr.Candrilli has conducted research to estimate the economic burden of various diseases and conditions, including diabetic microvascular complications, constipation, and traumatic injury. He has also conducted research to characterize patterns of medication utilization, including adherence and persistence, in patients with epilepsy. Additionally, Mr.Candrilli has analyzed numerous survey databases (including the National Health and Nutrition Examination Survey, the Medical Expenditure Panel Survey, and the Healthcare Cost and Utilization Project family of databases) to estimate the prevalence of various medical conditions and their associated economic burden.

Mr. Candrilli has coauthored research published in Managed Care Inter